Abstract

The present invention provides methods for to sex-specific treatment and dose titration of diseases associated with an aberrant functionality of activity-dependent neuroprotective protein (ADNP) and/or cytoskeleton such as progressive supranuclear palsy (PSP), schizophrenia, amnestic mild cognitive impairment (aMCI), Alzheimer's disease, and autism. The treatment in these diseases, e.g., the dose and/or the regimen, differs between sexes and has to be adapted to obtain the desired effect. Specifically, use of davunetide in treatment of women suffering from PSP or of men suffering from schizophrenia or aMCI are provided.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A process for generating hydrogen from a hydrocarbon, such a process for natural gas pyrolysis, or for a hydrocarbon reforming. The process includes interacting the hydrocarbon with a metal catalyst containing a mixture of at least two metals under conditions at which a solid phase of at least one of the metals and a liquid phase of the metal catalyst are simultaneously present. A system is for carrying out the process.

IPC Classes  ?

• C01B 3/26 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of gaseous or liquid organic compounds of hydrocarbons using catalysts

Abstract

Methods of predicting translation initiation efficiency in chloroplasts comprising calculating free folding energy of a region in a 5′ UTR, of a region in a16S rRNA, and of 5′ UTR region hybridized to the 16S rRNA region are provided. Methods of determining a region regulating translation of an mRNA in chloroplasts as well as methods of modulating translation of a target mRNA are also provided. mRNAs produced by methods of the invention and DNAs encoding those mRNAs are also provided.

IPC Classes  ?

• G16B 15/10 - Nucleic acid folding
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 30/10 - Sequence alignmentHomology search

Abstract

A light manipulation optical system comprises an electrical digital controller configured to receive digital electrical signals as input from an electrical bus, an array of optically coupled optical modulators, and optical ports arranged to feed the array with light and to deliver modulated light from the array. Each of at least a portion of the optical modulators can comprise a plurality of electrodes for modulating light propagating through the modulator, wherein the controller is also configured to digitally actuate the electrodes based on the signals.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• H04B 10/50 - Transmitters
• H04B 10/54 - Intensity modulation
• H04B 10/556 - Digital modulation, e.g. differential phase shift keying [DPSK] or frequency shift keying [FSK]
• G06E 1/04 - Devices for processing exclusively digital data operating upon the order or content of the data handled for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• G02F 1/31 - Digital deflection devices
• G02F 1/225 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference in an optical waveguide structure
• G06E 3/00 - Devices not provided for in group , e.g. for processing analogue or hybrid data
• G06N 3/067 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using optical means

Abstract

The present invention provides isolated monoclonal antibodies that specifically bind to Sialyl Lewis A (SLeA) glycan, fragments thereof and humanized version of said antibodies or fragments, as well as conjugates thereof. The invention further provides chimeric antigen receptors comprising said antibodies or fragments and cells, such as T cells comprising same. The invention further provides pharmaceutical compositions comprising all of the above agents and use of said agents and compositions for diagnosing and treating cancer characterized by overexpression of SLeA.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

A composition is disclosed which comprises solubilized decellularized omentum. Uses thereof and methods of generating same are also disclosed.

IPC Classes  ?

• C12N 5/0793 - Neurons
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/074 - Adult stem cells
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 9/76 - TrypsinChymotrypsin
• C12N 9/94 - Pancreatin

Abstract

The present invention provides phenoxy-dioxetane-based chemiluminescence probes having enhanced chemiexcitation and chemical stability, in which either an adamantyl derivative equipped with a hetero -functional group or a six-member carbocyclic or heterocyclic ring having an electron-withdrawing motif is spiro fused to the dioxetane. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.

IPC Classes  ?

• C07D 321/00 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• G01N 21/76 - ChemiluminescenceBioluminescence

Abstract

The invention presents a universal foundation model for decoding error correction codes (ECC) and a learning-based method for linear block ECCs. The foundation model is trained on multiple codes using a code-invariant embedding, relative positional encoding from derived from parity-check matrices, and a size-invariant transformation to generate a robust noise prediction. A learned distance embedding derived from each code's Tanner graph modulates self-attention, allowing the system to handle both seen and unseen codes without retraining. Overall, this approach replaces specialized, code-specific decoders with a single efficient model, enabling more robust and scalable decoding of diverse error correction codes. The linear block learning component based on the Transformer architecture allows the differentiable training of the code via the Tanner graph connectivity derivation from the parity check matrix, and enables the effective and differentiable joint optimization of the code and of the neural decoder.

IPC Classes  ?

• H03M 13/11 - Error detection or forward error correction by redundancy in data representation, i.e. code words containing more digits than the source words using block codes, i.e. a predetermined number of check bits joined to a predetermined number of information bits using multiple parity bits

Abstract

Compounds usable in treating a metabolic disorder associated with phenylalanine aggregation (fibril formation) and methods of identifying same are provided. The compounds include morin hydrate and structural analogs thereof and/or are collectively represented by Formula with the variables being as defined in the specification and claims. The compounds alternatively include those presented in Table 1 and/or compounds capable of aligning with a pharmacophoric model as described in the specification and drawings herein. Methods of identifying compounds capable of interfering with phenylalanine aggregation are also provided.

IPC Classes  ?

• C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
• C07D 311/32 - 2, 3-Dihydro derivatives, e.g. flavanones
• C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07D 487/04 - Ortho-condensed systems
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings

Abstract

The present disclosure provides reconstituted epitopes derived from viruses of the Flaviviridae family, as well as various polypeptides comprising the reconstituted epitopes disclosed herein. Specifically, the E protein of viruses of the Flaviviridae, and any domains thereof, particularly, the Dill domain, that comprise the reconstituted epitope of the present disclosure. The invention further provides vaccines, and compositions comprising the reconstituted epitopes, as well as therapeutic and prophylactic methods thereof.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to compositions and methods for overcoming functional redundancy in plants, particularly to methods for knocking-out and identifying multiple genes underlying a certain phenotype, utilizing multi-targeted genome-scale Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) applications.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present disclosure provides a laser-based proton acceleration system, comprising: a laser source configured to generate laser pulses suitable for inducing proton acceleration upon interaction with a target material; a laser focusing assembly configured to focus the laser pulses; a target including a suspended slat made of said target material and configured for liberating and accelerating protons upon interaction with said laser pulses. A slat thickness is such that electrons from a rear face of the suspended slat opposite to the front face significantly contribute to forming a normal sheath electric field. The laser source and the laser focusing assembly are configured so that laser pulses impinge on a front face of said suspended slat and a transverse cross section of said suspended slat may be fully immersed within a laser pulse focal volume.

IPC Classes  ?

• H05H 15/00 - Methods or devices for acceleration of charged particles not otherwise provided for
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The disclosure relates to methods for predicting allosteric inhibition of homologous to E6AP C-terminus (HECT) E3-ligases. The methods include in silico approaches for identifying small molecule allosteric inhibitors by threading amino acid sequences of target HECT ligases onto a template protein structure in its inhibited state, such as SMURF1, which comprises a cryptic allosteric cavity remote from the catalytic site and a glycine-hinge domain. The disclosure also enables screening and prediction of small molecule candidates capable of inducing allosteric changes, including elongation of the αH10 helix and shortening of the glycine-hinge domain, thereby restraining motion, essential for catalysis. The disclosed methods additionally provide validation of the predictions through structural and biochemical assays.

IPC Classes  ?

• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• C12N 9/10 - Transferases (2.)
• G16B 35/20 - Screening of libraries

Abstract

The present invention provides therapies for allergies. Specifically, the compositions of the present invention comprise engineered T cells comprising a chimeric antigen receptor that binds an IgE-BCR presented on B cells but not a secreted IgE. Therefore, the T cells eliminate IgE-producing B cells, prevent secretion of IgE and subsequently the symptoms of allergy.

IPC Classes  ?

• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/42 - Cancer antigens
• A61P 37/08 - Antiallergic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

Apparatuses, systems and methods for all-optical computing are disclosed. An optical computing apparatus includes a nonlinear optical crystal, at least one light source, and a detector. The at least one light source is configured to spatially modulate vectors of operand values onto coherent optical radiation and to direct the spatially modulated coherent optical radiation into the nonlinear optical crystal, thereby exciting propagating modes in the nonlinear optical crystal corresponding to a computational result of linear and nonlinear operations performed over the vectors. The detector is coupled to receive and sense the coherent optical radiation that has propagated through the nonlinear optical crystal so as to decode the computational result.

IPC Classes  ?

• G06E 1/02 - Devices for processing exclusively digital data operating upon the order or content of the data handled
• G06N 3/02 - Neural networks
• G02F 1/37 - Non-linear optics for second-harmonic generation
• G06N 3/067 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using optical means

Abstract

Apparatuses, systems and methods for all-optical computing are disclosed. An optical computing apparatus includes a multimode optical waveguide, at least one light source and a detector. The at least one light source is configured to spatially modulate vectors of operand values onto coherent optical radiation and to direct the spatially modulated coherent optical radiation into the multimode optical waveguide, thereby exciting propagating modes in the multimode optical waveguide whose overall operation corresponds to a matrix multiplying the vectors. The detector is coupled to receive and sense the coherent optical radiation that has propagated through the waveguide so as to decode a result of the matrix operation. In some embodiments, the multimode optical waveguide is coupled with a gain medium so as to apply a nonlinear operation on the propagating modes.

IPC Classes  ?

• G06N 3/067 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using optical means
• G06F 17/16 - Matrix or vector computation
• G06N 3/02 - Neural networks
• G02F 1/365 - Non-linear optics in an optical waveguide structure

Abstract

A method of detecting damage to sperm cell DNA molecules is disclosed. The method can be used for assessing whether sperm cells are a candidate for in-vitro fertilization, for diagnosing a disease associated with sperm cell damage or for detecting the effect of an agent on sperm cells.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention provides a chimeric DNA molecule including: (a) a first nucleic acid sequence encoding a polypeptide of interest, wherein a 3' end the first nucleic includes a stop codon; and (b) a second nucleic acid sequence encoding an endogenous polypeptide of a target cell, wherein the first nucleic acid sequence is located upstream to the second nucleic acid sequence in the chimeric DNA molecule, and wherein the first and second nucleic acid sequences are operably linked. Further provided is a method for increasing expression of a polypeptide of interest in a target cell, including culturing a cell including the chimeric DNA molecule, such that a polypeptide of interest encoded by the first nucleic acid sequence of the chimeric DNA molecule is expressed.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• C12N 15/67 - General methods for enhancing the expression
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

A method of diagnosing lung cancer in a subject-in-need thereof is provided. The method comprises: (a) providing a biological sample of the subject which comprises peripheral blood mononuclear cells (PBMCs); (b) in vitro contacting the PBMCs with a stimulant selected from the group consisting of the stimulants listed in Tables 3 and 4; and (c) measuring metabolic activity of the PBMCs having been contacted according to (b), wherein a statistically significant change in the metabolic activity of the PBMCs as compared to a control sample is indicative of lung cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A sensor and method for measuring enzymatic activity, such as cholinesterase (CHE) enzymatic activity. The sensor comprises a near-infrared (NIR) fluorescent single-walled carbon nanotube (SWCNT) functionalized with a substrate such as myristoylcholine (MC). Quantitative analysis correlates changes in fluorescence of the SWCNTs with enzymatic activity. A decrease in NIR fluorescence intensity of SWCNTs upon interaction of the substrate with the target enzyme allows real-time monitoring and is positively correlated with enzymatic activity. An absence of modulation of fluorescence of the SWCNTs is indicative of enzymatic inhibition and the presence of enzyme inhibitors.

IPC Classes  ?

• C12Q 1/46 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase involving cholinesterase
• C12N 9/18 - Carboxylic ester hydrolases
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• C01B 32/159 - Carbon nanotubes single-walled
• G01N 33/535 - Production of labelled immunochemicals with enzyme label

Abstract

An antireflective coating for reducing reflection of a wave off the coating, comprises a stack of layers, each having a discrete array of resonators characterized by a resonant wavelength within a spectral band of the wave, wherein at least two layers are characterized by different resonant wavelengths such that a set of resonant wavelengths of all layers discretely spans over the spectral band.

IPC Classes  ?

• G02B 1/11 - Anti-reflection coatings

Abstract

The present invention provides an array of microneedles composed of tri-block amphiphiles that can be programmed to undergo in situ sequential mesophase transitions for controlled drug release.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

A method of detecting the level of 5-hydroxymethylcytosines (5-hmc) in a DNA molecule of a cell having a 5-hmc prevalence lower than 0.002% of total DNA bases is provided. The method comprising: (a) attaching a 5-hmc labeling agent to the DNA molecule; and (b) subjecting the DNA molecule to an imaging method suitable for detecting the labeling agent, thereby detecting the level of 5-hmc in the DNA molecule. Also provided is a method of diagnosing cancer in a subject in need thereof, the method comprising: (a) providing a DNA sample of a cell of the subject; (b) detecting the level of 5-hmc in the DNA sample as described herein; wherein a significant decrease in the level of 5-hmc in the DNA sample, as compared to a control DNA sample from a healthy subject is indicative that the subject has cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules

Abstract

The present disclosure relates to immunotherapy. In more specific embodiments, the present disclosure provides systems, compositions, methods and uses of viral vectors comprising nucleic acid sequence of interest that encodes at least one therapeutic product, and a nucleic acid sequence encoding at least one nuclease, for in vivo targeted insertion of the nucleic acid sequence of interest into a target locus within at least one cell of the T lineage.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/725 - T-cell receptors
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

An Disclosed herein is an antenna device that includes a first transformer to output a harmonic component of a fundamental frequency and a leakage component at the fundamental frequency, a first frequency splitter outputting the harmonic component as a first transmission signal and outputting a first leakage signal, a first antenna element configured to radiate the first transmission signal; a second transformer to receive the first leakage signal and output a harmonic component of the fundamental frequency, a second frequency splitter outputting the harmonic component as a second transmission signal, and a second antenna element configured to radiate the second transmission signal. A plurality of transmission signals at harmonic frequencies may be radiated without the use of dividers, thus reducing a DC power consumption of antenna devices. This may increase a total radiated poser for an array area without requiring lenses.

IPC Classes  ?

• H01Q 1/52 - Means for reducing coupling between antennas Means for reducing coupling between an antenna and another structure
• H01Q 21/08 - Arrays of individually energised antenna units similarly polarised and spaced apart the units being spaced along, or adjacent to, a rectilinear path
• H01Q 23/00 - Antennas with active circuits or circuit elements integrated within them or attached to them

Abstract

Newly designed compounds represented by Formulae I-V as described in the instant specification and uses thereof as pancreatic endoplasmic reticulum kinase (PERK) activators and in treating associated medical conditions, including viral infections, are provided.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 31/14 - Antivirals for RNA viruses
• C07D 239/42 - One nitrogen atom

Abstract

The present invention is directed to, inter alia, a method for identifying a reference macromolecule for which a variant having improved function can be identified and/or engineered. Further provided is a macromolecule variant, such as, but not limited to Cas protein variant(s), being characterized by having improved function compared to a reference, and a method for designing same.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

A method for routing a Beneš network includes setting an initial state for a plurality of processing elements that represent switching elements of a first column, configuring the plurality of processing elements that represent the switching elements of the first column to communicate in a communication with each other to detect a plurality of collisions and to resolve the plurality of collisions by flipping states in a plurality of iterations, the communication performed by a centralized collision bus, and when the plurality of iterations are completed, resolving any remaining collisions, if any, by forfeiting an input demand from one colliding input port per a remaining collision, resulting in a reduction of utilization, wherein each bit in the centralized collision bus represents a switching element in the second set of switching elements.

IPC Classes  ?

• H04L 49/1515 - Non-blocking multistage, e.g. Clos
• H04L 49/253 - Routing or path finding in a switch fabric using establishment or release of connections between ports
• G06F 30/18 - Network design, e.g. design based on topological or interconnect aspects of utility systems, piping, heating ventilation air conditioning [HVAC] or cabling

Abstract

Compounds capable of activating an unfolded protein response (UPR) in a cell, for use in treating a viral infection in a subject in need thereof, are disclosed. The compounds can be PERK activators and/or compounds represented by Formula I as described in the specification.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim

Abstract

Provided are isolated p32 antibodies, chimeric antigen receptors comprising same, immune cells (e.g., T-cells) expressing same, nucleic acid constructs encoding same, pharmaceutical compositions comprising same and methods of treating p32-associated cancer using same. Exemplary scFv antibodies which are provided herein comprise SEQ ID NOs: 110, 111 and 100-109. Exemplary CAR sequences which are provided herein are set forth by SEQ ID NO: 82, 88 or 90.

IPC Classes  ?

• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention provides a composition comprising liquid-liquid phase separation (LLPS)-based compartments comprising a cationic peptide and an anionic polymer, variations and modifications thereof, methods for preparation of the LLPS-based compartments, and uses thereof for delivery or for controlling entrapping and releasing of a payload.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A robotic hand comprising: a set of at least two fingers having at least one compliant articulated finger comprising links, joints, and at least one tendon; and an actuating palm connected to the set of finger and operable to tense and relax the at least one tendon to cause least two of the fingers to respectively grip and release an object.

IPC Classes  ?

• B25J 15/08 - Gripping heads having finger members
• B25J 15/12 - Gripping heads having finger members with flexible finger members

Abstract

Disclosed herein is a system that includes a memory storing computer-readable instructions and at least one processor to execute the instructions to perform pre-training of a machine learning model using synthetic data including random music instrument digital interface (MIDI) files, receive a first library of audio files, receive a second library of MIDI files, each MIDI file having a corresponding audio file in the first library, align each midi file in the second library with the corresponding audio file in the first library, feed the first library and the second library into the machine learning model to train the machine learning model to perform musical transcribing of at least one musical instrument in an audio file, and receive an audio file and perform automatic transcription of at least one musical instrument in an audio file using the machine learning model based on expectation maximization.

IPC Classes  ?

• G10H 1/00 - Details of electrophonic musical instruments
• G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
• G06N 3/0895 - Weakly supervised learning, e.g. semi-supervised or self-supervised learning
• G06N 3/096 - Transfer learning

Abstract

A method of activating an immune response against brain metastasis in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an inhibitor of an MCP-1/CCR2/CCR4 axis, thereby activating the immune response against brain metastasis in the subject.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A method for identification of a multipotent mesenchymal stem cell subpopulation, among a heterogenic population of gastrointestinal tract mucosa mesenchymal stromal cells, is provided. Further provided is a kit including a probe for identification or isolation of gastrointestinal tract mucosa mesenchymal stem cells, and a pharmaceutical composition including enriched or isolated mesenchymal stem cell from the gastrointestinal tract mucosa, for treating an individual suffering from a disorder or a disease.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Method of increasing collagen production and tissue regeneration or repair using an agent that increases an amount of Hypoxia-inducible factor-1 (HIF-1) in the cells, the amount being selected to cause an increase in the amount of collagen production in the cells are disclosed. Also disclosed non-human cell cultures which comprise an activator of HIF-1.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

IPC Classes  ?

• C07C 211/22 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07C 59/01 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
• C07C 215/08 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
• C07C 219/04 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
• C07C 229/02 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
• C07C 229/10 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 233/00 - Carboxylic acid amides
• C07C 243/00 - Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
• C07C 243/10 - Hydrazines
• C07C 243/14 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07C 243/16 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
• C07C 243/26 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 243/28 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
• C07C 279/04 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
• C07C 333/10 - Monothiocarbamic acidsDerivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A T cell expressing an FC gamma receptor is provided. Accordingly there is provided a T cell genetically engineered to express a first polypeptide comprising an amino acid sequence of an Fc receptor common γ chain (FcRγ), said amino acid sequence is capable of transmitting an activating signal; and a second polypeptide comprising an extracellular ligand-binding domain of an Fcγ receptor capable of binding an Fc ligand and an amino acid sequence capable of recruiting said first polypeptide such that upon binding of said Fc ligand to said extracellular ligand-binding domain of said Fcγ receptor said activating signal is transmitted.

IPC Classes  ?

• C07K 14/735 - Fc receptors
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/32 - T-cell receptors [TCR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

Systems, methods, and computer readable media for identifying a person in a video are disclosed. Systems, methods, devices, and non-transitory computer readable media may include at least one processor that may be configured to generate a spatiotemporal emotion data compendium (STEM-DC) from the video and to process the STEM-DC using a deep fully adaptive graph convolutional network (FAGC) to determine a first person representation vector that represents the person in the video.

IPC Classes  ?

• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/40 - ScenesScene-specific elements in video content

Abstract

The technology disclosed herein concerns a process for fabricating devices with Graphene Nanogap Electrodes (GNE).

IPC Classes  ?

• H10F 71/00 - Manufacture or treatment of devices covered by this subclass
• H10F 77/12 - Active materials

Abstract

Provided is a hybrid hydrogel composition and methods for its preparation and use in 3D printing biomaterials for tissue engineering applications. The hybrid hydrogel composition comprises discrete hydrogel particles of a first crosslinked polymeric network, interpenetrated- through and threaded by a second crosslinked polymeric network, dispersed in a medium. The first polymer is a thermo-responsive polymer, while the second is a protein-based thermo¬ denaturing polymer. The process for preparing this composition involves mixing swelled hydrogel nanoparticles of the first polymer with a non-crosslinked hydrogel of the second polymer in the presence of a crosslinking agent for the first polymer. The 3D printing method utilizes this composition below the LCST of the thermo-responsive polymer, followed by temperature increase wherein the second polymer cures and fixes the printed ink. This approach enables the creation of high-resolution structures, including artificial tissues with capillary blood vessels, featuring dimensions less than 50 μm.

IPC Classes  ?

• B33Y 70/00 - Materials specially adapted for additive manufacturing
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• A61L 27/52 - Hydrogels or hydrocolloids
• C08J 3/075 - Macromolecular gels

Abstract

Pulmonary treatment methods and systems. During pulmonary treatment breath cycles, a hold period of elevated inspiration pressure may promote lung region filling (and potentially recruitment) via collateral airways. Expectoration is promoted by dropping from the inspiration pressure to an undershoot pressure; de-recruitment (e.g., by airway collapse) is mitigated by raising the undershoot pressure to a positive expiratory pressure (PEP) during expiration phase. Breath cycles with a period of post-PEP suction may also be administered. Respiratory therapy systems may be programmed or re-programmed to administer this pressure protocol. In some embodiments, a system includes a hand-held unit including a patient mouthpiece, a base unit which provides pressurized gas to the mouthpiece, an electronically controllable valve in the hand-held unit for providing therapy maneuvers such as PEP (Positive Expiratory Pressure) through the mouthpiece, and a computing unit which instructs the hand-held unit to perform therapy maneuvers.

IPC Classes  ?

• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61M 16/20 - Valves specially adapted to medical respiratory devices

Abstract

Provided herein is a see-through transparent, stable, safe and (bio)degradable hydrogel-based particulate support medium, made of calcium alginate particles. The calcium alginate particles, or hybrid hydrogel particles, are characterized by a substantially homogeneous average particle size that ranges from 0.1 micrometer to 5 micrometer.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/52 - Hydrogels or hydrocolloids
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• B33Y 80/00 - Products made by additive manufacturing

Abstract

A method of preventing or treating an infection caused by a microorganism in the oral cavity of a subject in need thereof is provided. The method comprising orally administering to the subject an oral care composition comprising an effective amount of at least one S100 protein, thereby treating or preventing the infection. Also provided is a method of preventing adhesion of a microorganism to a dental appliance or inhibiting growth thereon. In addition, provided are dental appliances, materials and compositions for oral care.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• A61P 35/00 - Antineoplastic agents

Abstract

A method to accelerate the growth rate and enhance the defense mechanisms of halophilic archaea microorganisms by mitigating the effects of proviruses within their genomes. The method involves identifying and deleting integrated proviruses from halophilic archaea cell genomes, exemplified by Haloferax strain 48N, which is chronically infected by HLSV1, a lemon-shaped circular virus. Utilizing a pop-in/pop-out protocol, upstream and downstream flanking regions of the provirus are cloned into a suicide plasmid and transformed into the host cell which is then subjected to selection in growth medium to produce a cell with a deleted provirus. Provirus deletion increases the growth rate and enhances the defense mechanisms of microorganisms by reducing the metabolic strain imposed by such proviruses. The disclosure extends to enhancing the growth rates of other genetically modified microorganisms through provirus mitigation.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 1/20 - BacteriaCulture media therefor

Abstract

A scalable centralized sorting algorithm based on finding the shortest conflict-free paths in a time-expanded representation space for a grid-based sorting system comprising an array of 4-way conveyors. The grid-based sorting system can move multiple unitary items simultaneously in directions towards their respective output cells, considerably improving throughput compared to conventional systems with comparable resources. The items are sorted by a grid of 4WCs according to their outputs. The entire process from the time the items are loaded into the system to the time they are ejected into their output cells, is fully automated, and the technology is entirely based on existing and proven electromechanical devices that have already been in use for material handling for years.

IPC Classes  ?

• B65G 47/68 - Devices for transferring articles or materials between conveyors, i.e. discharging or feeding devices adapted to receive articles arriving in one layer from one conveyor and to transfer them in individual layers to more than one conveyor, or vice versa, e.g. combining the flows of articles conveyed by more than one conveyor
• B65G 47/64 - Switching conveyors
• B65G 47/52 - Devices for transferring articles or materials between conveyors, i.e. discharging or feeding devices
• B65G 47/51 - Devices for discharging articles or materials from conveyors with distribution, e.g. automatically, to desired points according to unprogrammed signals, e.g. influenced by supply situation at destination
• B65G 47/71 - Devices for transferring articles or materials between conveyors, i.e. discharging or feeding devices adapted to receive articles arriving in one layer from one conveyor and to transfer them in individual layers to more than one conveyor, or vice versa, e.g. combining the flows of articles conveyed by more than one conveyor the articles being discharged to several conveyors
• B65G 47/42 - Devices for discharging articles or materials from conveyors operated by article or material being conveyed and discharged
• B07C 5/36 - Sorting apparatus characterised by the means used for distribution
• B65G 29/00 - Rotary conveyors, e.g. rotating discs, arms, star-wheels or cones

Abstract

A dynamic vision sensor (DVS) color camera (DVS-CCam) operable to acquire a color image of a scene, the DVS-CCam including a DVS photosensor comprising DVS pixels, an illuminator operable to transmit a light pattern characterized by temporal changes in intensity and color to illuminate a scene, an optical system configured to collect and focus on the pixels of the DVS photosensor light reflected by features in the scene from the light pattern transmitted by the illuminator, and a processor configured to process DVS signals generated by the DVS pixels responsive to temporal changes in the reflected light to provide a color image of the scene.

IPC Classes  ?

• H04N 25/47 - Image sensors with pixel address outputEvent-driven image sensorsSelection of pixels to be read out based on image data
• H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means
• H04N 23/74 - Circuitry for compensating brightness variation in the scene by influencing the scene brightness using illuminating means
• H04N 23/84 - Camera processing pipelinesComponents thereof for processing colour signals
• H04N 25/707 - Pixels for event detection

Abstract

The present invention provides a method for rapid detection and identification of a pathogenic bacteria in an aqueous medium, by creating a unique enzymatic activity fingerprint of said bacteria using an array of chemiluminescent probes each composed of a phenyl-dioxetane luminophore masked by a caging group cleavable by a bacterial analyte or enzyme; and a computing system for implementing said method.

IPC Classes  ?

• G01N 27/76 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids by investigating susceptibility
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present invention relates to systems and methods for inducing and analyzing gene knockdown and/or knockout in plants at a large-scale. In particular, the present invention discloses Cell type-specific Multi-targeted AmiRNA or CRISPR (cMAC) function-scale toolbox, presenting a novel system for knockdown and/or knockout of gene families at the functional-scale, for example, at the transportome scale, and at the cell type level.

IPC Classes  ?

• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

There is provided a method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving EEG datasets from EEG electrodes monitoring a head of the subject, computing events for the EEG datasets, clustering the events into clusters, computing a p-adic representation of the clusters, extracting a p-adic topology from the p-adic representation of the clusters, computing a personal universal dendrogramic holographic signature (PUDHS) of the p-acid topology relative to a personalized threshold that separates between a relative large distance between events and a relatively small distance between events, the PUDHS denoting number of events below the personalized threshold, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the PUDHS relative to a medical threshold that separates between presence of the medical state and non-presence of the medical state.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

The invention relates to a process and a system for 3-dimentional (3D) fabrication of sub-micron structures and is established by local electrochemical deposition methods.

IPC Classes  ?

• B29C 64/165 - Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
• B22F 10/10 - Formation of a green body
• B22F 10/32 - Process control of the atmosphere, e.g. composition or pressure in a building chamber
• B22F 10/85 - Data acquisition or data processing for controlling or regulating additive manufacturing processes
• B22F 12/90 - Means for process control, e.g. cameras or sensors
• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• C25D 1/00 - Electroforming
• C25D 5/04 - Electroplating with moving electrodes
• C25D 21/12 - Process control or regulation

Abstract

The present disclosure describes a chimeric antigen receptors (CAR) that allow a cell of the B cell lineage to undergo antigen-induced activation independent of a cell of T cell lineage, compositions thereof, and method of use thereof for genetically modifying a cell of the B cell lineage or treating a subject suffering from a pathological disorder.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 14/725 - T-cell receptors
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

A method of preparing an electrochemically active component made of a 3D porous graphene matrix and electrochemically active material dispersed and/or entrapped within the matrix, and electrochemically active components obtained by this method are provided. The method is effected by depositing a mixture of a carbonaceous material and an electrochemically active material onto a conductive substrate, and exposing the conductive substrate to laser irradiation. Electrochemical systems integrating the electrochemically active component, for example, as an electrode such as an anode in alkali metal ion batteries and methods of preparing same are also provided.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/133 - Electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/1393 - Processes of manufacture of electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• C01B 32/184 - Preparation
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

A method of preparing an electrochemically active component made of a jellyfish-derived graphene matrix and electrochemically active material dispersed and/or entrapped within the matrix, and electrochemically active components obtained by this method are provided. The method is effected by depositing a mixture of a carbonaceous material that contains a jellyfish biomass and an electrochemically active material onto a conductive substrate, and exposing the conductive substrate to laser irradiation. Electrochemical systems integrating the electrochemically active component, for example, as an electrode such as an anode in alkali metal ion batteries and methods of preparing same are provided. A method of preparing a graphene matrix made of a jellyfish-derived graphene matrix, and a graphene matrix obtained by this method, are also provided.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• C01B 32/184 - Preparation
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

Methods of optimizing an antibody coding sequence, comprising providing a nucleic acid sequence comprising a coding region encoding an antibody and producing at least one synonymous mutation wherein the mutation converts at least one codon into a codon more commonly used in a set of genes consisting of a plurality of nucleic acid sequences encoding antibodies are provided. Nucleic acid molecule systems comprising an optimized coding sequence are also provided.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G16B 20/50 - Mutagenesis

Abstract

A method of treating a brain tumor in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating activity or expression of a component of the lipid synthesis and/or transportation pathways in an astrocyte in the tumor microenvironment and/or a therapeutically effective amount of a molecule which is associated with lipid uptake by the tumor cells or immune cells in the tumor microenvironment, or a polynucleotide encoding same.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A method of calibration for a radar array including: receiving a plurality of measurement vectors, each measurement vector associated with a range-Doppler (RD) cell of a RD map; determining from the plurality of measurement vectors a plurality of autocorrelation matrices, an autocorrelation matrix corresponding to each the measurement vector and RD cell; performing an iterative process to minimize a cost function to provide an optimized calibration matrix configured to cancel radar array non-idealities, the process comprising: transforming the plurality of autocorrelation matrices with a hypothesized calibration matrix; smoothing the plurality of transformed autocorrelation matrices using one or more subarray technique to provide a plurality of smoothed autocorrelation matrices; determining a discrepancy function for each of the smoothed autocorrelation matrices and for each of a plurality of hypothesized numbers of targets, to provide, for each smoothed autocorrelation matrix, a plurality of likelihood functions, one for each hypothesized number of targets; selecting, for each of the smoothed autocorrelation matrices, a minimal likelihood function corresponding to a single hypothesized number of targets; and summing the selected minimal likelihood functions to provide the cost function.

IPC Classes  ?

• G01S 7/40 - Means for monitoring or calibrating
• G01S 7/4912 - Receivers

Abstract

The present invention relates to a method for the generation of outer radial glial (oRG) cells of the outer sub-ventricular (oSVZ)-like region in cerebral organoids comprising (a) culturing primate stem cells in a primate stem cell medium until about day 6, thereby inducing the formation of embryonic bodies; (b) culturing the embryonic bodies as obtained in step (a) in a neural induction medium until about day 11, thereby inducing the formation of organoids; wherein an inhibitor of TGF-β, an inhibitor of BMP and an inhibitor of WNT is present from about day 2 until about day 11; (c) embedding the organoids as obtained after steps (a) and (b) and if they display a size of at least 300 μm into a hydrogel that mimics the extracellular matrix (ECM), preferably Matrigel and culturing the organoids in a cerebral differentiation medium at least until about day 40, preferably at least until about day 60 and most preferably at least until about day 80, thereby obtaining cerebral organoids with oRG cells in oSVZ-like regions, wherein the organoids in step (c) are subjected to agitation from about day 15 onward, preferably by using an orbital shaker or a spinning bioreactor; and (d) optionally isolating one or more oRG cells from the oSVZ-like region.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12N 5/0793 - Neurons

Abstract

The present disclosure relates to a methods, compositions and kits for the diagnosis and prognosis of sepsis and/or associated conditions, as well as tailoring personalized treatment regimens based on the balance between systemic inflammation and resistance state of subjects in need. The disclosed methods involve calculating the resistance (R) level and the systemic inflammation (SI) level of a subject to determine a R/SI balance score that enables classification of the subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A method for producing a nanostructure layer stack having a plurality of N nanostructure layers adhered together, the method comprising: fabricating at least one nanostructure layer of N nanostructure layers comprised in a nanostructure stack on a substrate that is not another of the N nanostructure layers: vetting the at least one nanostructure layer to determine if the at least one nanostructure layer satisfies a quality constraint; and if the at least one nanostructure layer satisfies the quality constraint, adhered each of the at least one nanostructure layer to another nanostructure layer of the N nanostructure layers to form the nanostructure stack.

IPC Classes  ?

• B32B 37/02 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by a sequence of laminating steps, e.g. by adding new layers at consecutive laminating stations
• B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
• B32B 37/12 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by using adhesives

Abstract

Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.

IPC Classes  ?

• A61K 35/68 - Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
• C07K 14/45 - Toxoplasma
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

A system which can be used for carrying out a method for determining an efficacy of a transcranial magnetic stimulation (TMS) treatment, including: delivering TMS to a patient using a TMS protocol in a TMS treatment session; recording EEG signals before and after the delivering during the treatment session; recording EEG signals after completion of the treatment session; analyzing the recorded EEG signals to generate values of one or more EEG parameters; determining an acute effect and an intermediate effect of the TMS protocol on a brain state of the patient based on a change in values of the one or more EEG parameters; determining an efficacy of the TMS protocol based on the determined acute effect and the intermediate effect.

IPC Classes  ?

• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

Methods and compositions are disclosed for treating myelin structural deficiencies and restoring normal myelin structure. This is achieved by downregulating Qki to increase Myelin Basic Protein (MBP) production, using selective serotonin reuptake inhibitors (SSRIs) such as citalopram to enhance expression of miR-30b-5p and miR-101a-3p. miRNA mimics can also be employed to achieve similar outcomes. The methods include administering SSRIs, miRNA mimics, utilizing Adeno-Associated Virus (AAV) vectors for gene delivery, or using intranasal delivery systems for encapsulated miRNAs. These approaches are applicable to a range of conditions, including Major Depressive Disorder (MDD), schizophrenia, bipolar disorder, and other CNS disorders. Methods for developing therapeutic agents, assessing treatment efficacy, and detecting said conditions using biomarkers of miR-30b-5p, miR-101a-3p, and Qki are also disclosed.

IPC Classes  ?

• A61K 31/04 - Nitro compounds
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Provided are isolated chimeric polypeptides and composition-of matters comprising a cell penetrating peptide (CPP) being conjugated to a heterologous moiety-of-interest, wherein the CPP: (i) comprising an amino acid sequence which does not exceed 30 amino acids in length, (ii) comprising an RGFRRR loop as set forth by SEQ ID NO: 2 and (iii) having at least 80% global sequence identity to SEQ ID NO: 1. Also provided are isolated peptides comprising an amino acid sequence which does not exceed 30 amino acids in length and being a cell penetrating peptide (CPP), the amino acid sequence: (i) comprising an RGFRRR loop as set forth by SEQ ID NO: 2, (ii) comprising at least one synthetic modification; and (iii) having at least 80% global sequence identity to SEQ ID NO: 1; and methods and compositions using and comprising same.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Some embodiments relate to a data analysis system is presented for inspecting unstained biological cells during fast flow. The data analysis system comprises: a data input utility, and data processor. The data input utility receives raw measured data comprising measured data pieces corresponding to a stream of raw data containing wavefront acquisitions collected from said unstained biological cell under inspection being obtained from the unstained biological cell during the fast flow. The data processor and analyzer is configured and operable to apply to said raw measured data real time processing by a trained neural network model and extract cell-related data.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/10 - Investigating individual particles
• G01N 15/1434 - Optical arrangements
• G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
• G03H 1/04 - Processes or apparatus for producing holograms
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

The present invention is in the field of molecular hydrogen (H2) bio-production, particularly, the present invention provides genetically modified photosynthetic microalgae producing hydrogen in complete growth medium under ambient, continuous growth conditions at cost-effective amounts and to a process for hydrogen production using genetically modified photosynthetic microalga.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• C12R 1/89 - Algae

Abstract

Provided herein are devices, systems and methods for restoring tactile sensation in a subject, using a subcutaneously implanted nanogenerator which is connected to at least one of the subject's sensory nerves and is configured to produce an electric signal upon external stimulus and provide the electric signal to the sensory nerve to thereby stimulate the nerve in accordance with the external stimulus.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/378 - Electrical supply

Abstract

The present invention is directed to a method for treating cancer in a subject determined as having the presence of a G600>A substitution, a C601>T substitution, or both, in the B cell lymphoma 2 (BCL2) gene of a cell.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• C12N 15/67 - General methods for enhancing the expression
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method of detecting a presence, amount and/or type of an electroactive (electrochemically detectable) drug such as cannabinoids and amphetamines in a gaseous sample is provided. The method is effected by contacting the sample with a carbon electrode; applying potential to the electrode; and measuring an electrochemical parameter of the carbon electrode, wherein the electrochemical parameter is indicative of a presence and/or amount and/or type of the electroactive drug in the sample. Carbon electrodes, electrochemical cells comprising same and devices or systems comprising the electrochemical cells, which are configured for detecting electroactive drugs in a gaseous sample, are also provided.

IPC Classes  ?

• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 27/403 - Cells and electrode assemblies
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

Methods, compositions, systems, matrices, and kits for determining a presence, type and/or amount of a viral biomarker in a sample by contacting the sample with one or more agents that selectively reacts with the a biomarker and with a colorimetric indicator that exhibits a colorimetric change as a result of a reaction between the agent and a viral biomarker, are provided.

IPC Classes  ?

• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Uses of ADNF polypeptides in therapy are provided. Accordingly, there is provided a method of treating a disease associated with visual evoked potential impairment and/or speech impairment that is not due to vocal disturbance and in which the subject suffers from the visual evoked potential impairment and/or speech impairment, the method comprising administering to the subject a therapeutically effective amount of an ADNF polypeptide, wherein said ADNF polypeptide has a neurotrophic/neuroprotective activity in an in vitro cortical neuron culture assay.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Compositions and articles comprising an ADNF polypeptide are provided. Accordingly, there is provided an article of manufacture comprising as active ingredients an ADNF polypeptide and a SIRT1 activator. Also provided are methods of treating a disease that can benefit from the article of manufacture.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

The present invention provides a catalyst comprising metallic nanoparticles made of same or different metal atoms, anchored to an oxide-based support comprising metal ions, wherein said metal atoms comprise Ru(0), Fe(0), and optionally Cu(0) and/or Ag(0); and said metal ions comprise at least two of Sr(II), La(III), Ca(II), Ba(II), Pr(III), Nd(III), Zr(III), Y(III), and Cs(I), and optionally Fe(III) and/or Fe(II). The catalyst is useful in a process for the production of ammonia, which may be carried out under conditions that greatly reduce the capital- and operational expenditures of ammonia production by comparison to the current Haber-Bosch process; and is assumed to be further useful in a process for ammonia cracking.

IPC Classes  ?

• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 23/745 - Iron
• B01J 23/72 - Copper
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 23/76 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups
• B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
• B01J 23/58 - Platinum group metals with alkali- or alkaline earth metals or beryllium
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C01C 1/04 - Preparation of ammonia by synthesis
• B01J 23/50 - Silver

Abstract

Methods of detecting oncogenic phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), diagnosing cancer and determining suitability of a subject suffering from cancer to be treated with a PI3K inhibitor comprising detecting the presence of a cytosine at position 179203524 on chromosome 3 of hg38 are provided, as are methods of treating a subject suffering from a cancer comprising a cytosine at position 179203524 on chromosome 3, by administering a PI3K/AKT pathway inhibitor. Nucleic acid molecules and kits that differentiate between a cytosine and a guanine at position 179203524 on chromosome 3 of hg38 are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/33 - Heterocyclic compounds
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

A method of treating brain-metastasized cancer in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically decreases an amount and/or activity of P-selectin and an immunomodulatory agent. Methods of treating additional cancers are also disclosed.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to methods for isolating a population of tumor cells from biological samples, to population of tumor cells and uses thereof.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• C12N 5/09 - Tumour cells

Abstract

A method of treating an inflammatory disease or disorder of the central nervous system (CNS) in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of binding CD157 on CD157-expressing cells of the CNS, the agent capable of mediating a therapeutic effect.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/00 - Drugs for disorders of the nervous system
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A novel dual-acting class of antifungal compound synthesized by linking an azole pharmacophore to a COX inhibitor to form a hybrid molecule. A method of making the antifungal compound by preparing a mixture of an azide-functionalized pharmacophore, subjecting the azide-functionalized pharmacophore to catalytic hydrogenation to obtain an amine-functionalized azole pharmacophore, and coupling a COX inhibitor to the amine-functionalized azole pharmacophore. A method for treating fungal infection in plants and animals comprising administering the antifungal compound.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A01N 43/653 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• A01P 3/00 - Fungicides
• A61P 31/10 - Antimycotics

Abstract

Embodiments of a system and method of treating tics in a subject, by at least one processor, may include: displaying an audiovisual stimulus to the subject, and obtaining indication of onset of tic sequences in the subject. The tic sequences may include one or more tics, subsequent to the audiovisual stimulus display. Embodiments of the invention may calculate one or more tic property values, representing one or more respective characteristics of the tic sequences, and subsequently adjust the audiovisual stimulus in real time, based on the one or more tic property values, so as to encourage the subject to prolong time gaps between subsequent tic sequences.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• A61B 5/375 - Electroencephalography [EEG] using biofeedback

Abstract

A machine vision system for larval aquatic animal rearing constituted of a video camera, a watertight housing and a processor, wherein the video camera is arranged to continuously capture video of a predetermined volume and transmit the captured video to the processor, and wherein the processor is arranged to apply one or more neural networks to the captured video to: isolate individual aquatic animal within the video: identify at least one predetermined activity parameter and/or at least one predetermined morphological anomaly of the isolated aquatic animal.

IPC Classes  ?

• A01K 29/00 - Other apparatus for animal husbandry
• A01K 61/10 - Culture of aquatic animals of fish
• G06V 10/147 - Details of sensors, e.g. sensor lenses
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/40 - ScenesScene-specific elements in video content
• G06V 20/52 - Surveillance or monitoring of activities, e.g. for recognising suspicious objects
• G06V 40/10 - Human or animal bodies, e.g. vehicle occupants or pedestriansBody parts, e.g. hands
• G06V 40/20 - Movements or behaviour, e.g. gesture recognition
• H04N 23/51 - Housings
• H04N 23/56 - Cameras or camera modules comprising electronic image sensorsControl thereof provided with illuminating means

Abstract

A computer-implemented method comprising: receiving a plurality of gaze vectors associated with a cohort of subjects, wherein each of the gaze vectors represents tracking of a point-of-gaze of one of the subjects while performing a cognitive task; and at a training stage, training a machine learning model on a training dataset comprising: (i) all of the gaze vectors, and (ii) annotations indicating a depression score of each of the subjects, to obtain a trained machine learning model configured to issue a prediction of depression in a target subject, based on target gaze vectors obtained from gaze tracking recording of the target subject while performing the cognitive task.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

In a system for converting digital data into a modulated optical signal, an electrically controllable device, including a modulator having one or more actuating electrodes, provides an analog-modulated optical signal that is modulated in response to output data bits of a digital-to-digital mapping. A digital-to-digital conversion provides the mapping of input data words to the output data bits. The mapping enables adjustments to correct for non-linearities and other undesirable characteristics, thereby improving signal quality.

IPC Classes  ?

• H03M 1/00 - Analogue/digital conversionDigital/analogue conversion
• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• G02F 1/225 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference in an optical waveguide structure
• G02F 7/00 - Optical analogue/digital converters
• H03M 1/70 - Automatic control for modifying converter range
• H04B 10/25 - Arrangements specific to fibre transmission
• H04B 10/2575 - Radio-over-fibre, e.g. radio frequency signal modulated onto an optical carrier
• H04B 10/50 - Transmitters
• H04B 10/516 - Details of coding or modulation
• H04B 10/54 - Intensity modulation
• H04B 10/556 - Digital modulation, e.g. differential phase shift keying [DPSK] or frequency shift keying [FSK]
• G02F 1/015 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on semiconductor elements having potential barriers, e.g. having a PN or PIN junction
• G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference

Abstract

Bioink compositions comprising a plurality of aromatic peptides and a matrix-forming material, formulations and kits for preparing same, additive manufacturing (bioprinting) processes utilizing same and three-dimensional objects obtained thereby are provided.

IPC Classes  ?

• C09D 11/04 - Printing inks based on proteins
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/52 - Hydrogels or hydrocolloids
• B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
• B29K 105/00 - Condition, form or state of moulded material
• B29L 31/00 - Other particular articles
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing
• C08L 89/06 - Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin

Abstract

Systems, methods, and computer readable media for identifying a person in a video are disclosed. Systems, methods, devices, and non-transitory computer readable media may include at least one processor that may be configured to generate a spatiotemporal emotion data compendium (STEM-DC) from the video and to process the STEM-DC using a deep fully adaptive graph convolutional network (FAGC) to determine a first person representation vector that represents the person in the video.

IPC Classes  ?

• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/40 - ScenesScene-specific elements in video content

Abstract

The presently disclosed subject matter discloses (i) a hardware design for a combinational circuit (i.e., single clock cycle) that supports operations over the Fano- Elias encoding (FE-encoding) (e.g., insertions, deletions, and queries); (ii) a hardware design for a dynamic data- structure for approximate membership (i.e., a filter) that maintains a set subject to insertions, deletions, and approximate membership queries, and (iii) a parallel architecture for a dynamic data- structure for approximate membership (i.e., a filter) that maintains a set subject to insertions, deletions, and approximate membership queries.

IPC Classes  ?

• H03M 7/40 - Conversion to or from variable length codes, e.g. Shannon-Fano code, Huffman code, Morse code
• H03M 7/00 - Conversion of a code where information is represented by a given sequence or number of digits to a code where the same information is represented by a different sequence or number of digits
• H03M 7/30 - CompressionExpansionSuppression of unnecessary data, e.g. redundancy reduction

Abstract

A phase shifter including: an upconversion mixer configured to receive a local oscillator (LO) signal having a LO frequency, and configured to receive and multiply a radio frequency (RF) input signal with the LO signal to produce a modulated signal having two sidebands around the LO frequency, an intermediate IF sideband having frequency below the LO and an image sideband; a filter connected to and configured to receive the modulated signal from the upconversion mixer and to attenuate a range of frequencies corresponding to the image sideband to select and output the intermediate frequency (IF) sideband signal; and a downconversion mixer configured to receive and multiply the IF sideband signal with a phase shifted LO signal to produce an output signal including a phase shifted version of the RF input signal.

IPC Classes  ?

• H01P 1/18 - Phase-shifters
• H03H 11/20 - Two-port phase shifters providing an adjustable phase shift
• H03B 5/24 - Generation of oscillations using amplifier with regenerative feedback from output to input with frequency-determining element comprising resistance and either capacitance or inductance, e.g. phase-shift oscillator active element in amplifier being semiconductor device

Abstract

The present invention provides lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for in vivo therapeutic applications. The lipids of the present invention are characterized as particularly hydrolytically and alcoholytically stable, while maintaining their biological activity.

IPC Classes  ?

• C07C 271/10 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 211/22 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
• C07C 219/04 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided herein compositions including collagenase, and uses thereof in orthodontic procedures, wherein the compositions may include recombinant collagenase and/or modified forms of recombinant collagenase having amino acid(s) truncation or substitutions.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 6/00 - Preparations for dentistry
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Multi subunit protein modules are provided. Accordingly, there is provided a multi subunit protein module comprising at least three cell membrane polypeptides each comprising an amino acid sequence of an Fc receptor common gamma chain (FcRgamma), said amino acid sequence is capable of transmitting an activating signal; wherein at least one but not all of said at least three polypeptides comprises an extracellular binding domain capable of binding a target that is presented on a cell surface of a target cell of an immune cell, such that upon binding of said extracellular binding domain to said target said activating signal is transmitted in an immune cell expressing said multi subunit protein module. Also provided are cells expressing the multi subunit protein modules and uses thereof.

IPC Classes  ?

• C07K 14/735 - Fc receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

A device and method for resonant pumping of optical gain medium, comprising an electrical pump, an ultracoherent microlaser, and a plasma microresonator. The ultracoherent microlaser can comprise an orthogonal laser supported by a whispering-gallery disk resonator. The electrical pump can electrically pump plasma to trigger a semiconductor laser with 1centimeter coherence to orthogonally resonantly enhance an ultracoherent laser. For a disk thickness near 1 micron, a factor of 20,000x in resonantly enhancing pump efficiency is achievable. The plasma microresonator can also comprise microbubble cavities, argon plasma, and walls thinner than an optical wavelength.

IPC Classes  ?

• H01S 3/06 - Construction or shape of active medium
• H01S 3/16 - Solid materials
• H01S 3/091 - Processes or apparatus for excitation, e.g. pumping using optical pumping
• H01S 3/17 - Solid materials amorphous, e.g. glass
• H05H 1/24 - Generating plasma
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

Provided herein are methods of controlling gene expression by modifying plasmid copy number to a pre-determined copy number per a need of a user.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided is a cannabinoid-phospholipid conjugate where the cannabinoid is covalently linked, via a cleavable linker, to a polar head group of the phospholipid. Also provided is a method of obtaining the conjugate, the method comprising (a) reacting the phospholipid (PL) dissolved in an organic solvent with maleic anhydride (MA) to obtain PL-MA intermediate; and (b) reacting said PL-MA intermediate with the cannabinoid in the presence of a carboxyl activating agent and an esterification agent to obtain a reaction mixture comprising said conjugate. Uses of the conjugate are also disclosed.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Core-shell microstructures made of a polymeric outer shell and a porous inner core that comprises a chemically-crosslinked polyamine, methods of preparing same and uses thereof are provided. The microstructures can be obtained, for example, by wet spinning, for example, wet mechanical spinning or by wet electrospinning using a solution comprising a polymeric material that forms an outer shell and a solution comprising a polyamine, and a hydrogel matrix that comprises a crosslinker for forming the chemically-crosslinked polyamine in the inner core.

IPC Classes  ?

• C08G 73/02 - Polyamines
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• B01J 13/02 - Making microcapsules or microballoons

Abstract

A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein is an energy harvesting module, including an antenna having a planar radiator and configured to receive incoming electromagnetic radiation and generate an AC antenna signal; a rectifier circuit arranged in a plane parallel to and adjacent to the planar radiator and configured to rectify the AC antenna signal and generate a DC battery charging signal; and a battery configured to receive the DC battery charging signal.

IPC Classes  ?

• H02J 50/00 - Circuit arrangements or systems for wireless supply or distribution of electric power
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
• H02M 7/217 - Conversion of AC power input into DC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only

Abstract

The present invention provides organoids comprising cultured bovine myogenic progenitor cells, methods for their preparation in suspension from bovine pluripotent stem cells, and uses thereof for preparing cultured meat.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A23L 13/00 - Meat productsMeat mealPreparation or treatment thereof
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

A method for predicting risk of a subject to dental caries, the method comprising obtaining a sample of saliva from a subject, allowing natural saliva antibodies to bind to specific proteins or polypeptides to generate a protein or polypeptide binding profile of the sample associated with immunorecognition of S mutans secreted proteins or polypeptides in the subject and comparing the generated protein or polypeptide binding profile with a reference protein or polypeptide binding profile to determine risk of the subject to dental caries.

IPC Classes  ?

• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci

Abstract

A novel nano-carrier system and method include a virus-like particle, and a functional RNA encapsulated inside the virus-like particle. The virus-like particle protects the functional RNA from nuclease degradation in vivo, and the functional RNA maintains its functionality while being encapsulated inside the virus-like particle. The system and method may be used to modify, reduce, or treat a disease in a subject.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A23L 13/00 - Meat productsMeat mealPreparation or treatment thereof
• A61K 9/51 - Nanocapsules
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.

IPC Classes  ?

• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/08 - Bridged systems

Abstract

Methods of determining a type of cancer in a subject or estimating survival time after diagnosis of a subject comprising employing a machine learning model to evaluate mutations that are not exonic non-synonymous mutations are provided. Methods comprising training a machine learning model are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 40/20 - Supervised data analysis